Lanean...
The Eltrombopag antitumor effect on hepatocellular carcinoma
Currently, sorafenib is the only available chemotherapeutic agent for advanced hepatocellular carcinoma (HCC), but it cannot be used in patients with liver cirrhosis (LC) or thrombocytopenia. In these cases, sorafenib is likely effective if given in combination with treatments that increase the numb...
Gorde:
| Argitaratua izan da: | Int J Oncol |
|---|---|
| Egile Nagusiak: | , , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
D.A. Spandidos
2015
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4599203/ https://ncbi.nlm.nih.gov/pubmed/26397763 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ijo.2015.3180 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|